Solve Therapeutics Acquires Cereius, a Duke University Spin-Out

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.

Solvias Acquires Cergentis

July 13, 2022

Biotechnology

Swiss analytical contract research and manufacturing company Solvias acquired Utrecht-based genomics services provider Cergentis on July 12, 2022. The deal adds Cergentis' proprietary Targeted Locus Amplification (TLA) genomic analysis capabilities to Solvias' biologics and cell & gene therapy testing platform to expand its advanced-therapy testing services globally.

Ariceum Therapeutics Acquires Theragnostics Ltd.

June 1, 2023

Biotechnology

Ariceum Therapeutics has acquired 100% of Theragnostics Ltd., a UK-based developer of radiopharmaceutical diagnostic and therapeutic products, for $2.5 million upfront plus up to $41.5 million of milestone payments. The deal gives Ariceum late preclinical/early clinical PARP inhibitor assets, US FDA‑approved NEPHROSCAN™ (partnered with GE Healthcare) and expanded US operations, strengthening its diagnostic and therapeutic radiopharmaceutical pipeline.

TenX Keane Acquisition Merges with Citius Pharmaceuticals' Oncology Subsidiary to Form Citius Oncology, Inc.

August 12, 2024

Biotechnology

TenX Keane Acquisition (Nasdaq: TENK) completed a merger with Citius Pharmaceuticals' wholly owned oncology subsidiary to form the publicly traded Citius Oncology, Inc. Citius Pharmaceuticals retains approximately 90% ownership of the new company, which will commercialize the recently FDA-approved oncology therapy LYMPHIR and trade on Nasdaq under the ticker CTOR.

QuartzBio (Precision for Medicine) Acquires SolveBio

January 24, 2023

Cloud & SaaS

QuartzBio, a business unit of Precision for Medicine, has acquired SolveBio and integrated its enterprise biomarker and genomic data management platform into QuartzBio’s end-to-end SaaS suite. The acquisition expands QuartzBio’s capabilities for sample inventory, biomarker data management and enterprise-level visibility to better serve pharmaceutical and biotech clients in clinical research and development.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.